Accession Number: | 0000899243-19-008806 |
Date: | 2019-03-22 |
Issuer: | NANOSTRING TECHNOLOGIES INC (NSTG) |
Original Submission Date: |
CLARUS LIFESCIENCES II, L.P.
C/O CLARUS VENTURES,
101 MAIN STREET, SUITE 1210
CAMBRIDGE, MA 02142
CLARUS VENTURES II GP, L.P.
C/O CLARUS VENTURES
101 MAIN STREET, SUITE 1210
CAMBRIDGE, MA 02142
BLACKSTONE CLARUS II L.L.C.
C/O THE BLACKSTONE GROUP L.P.
345 PARK AVENUE
NEW YORK, NY 10154
BLACKSTONE HOLDINGS II L.P.
C/O THE BLACKSTONE GROUP L.P.
345 PARK AVENUE
NEW YORK, NY 10154
BLACKSTONE HOLDINGS I/II GP INC
C/O THE BLACKSTONE GROUP L.P.
345 PARK AVENUE
NEW YORK, NY 10154
BLACKSTONE GROUP L.P.
345 PARK AVENUE
NEW YORK, NY 10154
BLACKSTONE GROUP MANAGEMENT L.L.C.
C/O THE BLACKSTONE GROUP L.P.
345 PARK AVENUE
NEW YORK, NY 10154
SCHWARZMAN STEPHEN A
C/O THE BLACKSTONE GROUP L.P.
345 PARK AVENUE
NEW YORK, NY 10154
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2019-03-22 | S | 2,000,000 | d | $21.62 | 2,036,025 | indirect | f2,f3,f4 |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | this amount represents the $23.00 public offering price per share of common stock, par value $0.0001 per share, of nanostring technologies, inc. (the "issuer"), less the underwriting discount of $1.38 per share. |
f2 | these securities are held directly by clarus lifesciences ii, l.p. ("clarus ii"). clarus ventures ii gp, l.p. ("clarus ii gp") is the sole general partner of clarus ii. blackstone clarus ii l.l.c. is the sole general partner of clarus gp. the sole member of blackstone clarus ii l.l.c. is blackstone holdings ii l.p. the sole general partner of blackstone holdings ii l.p. is blackstone holdings i/ii gp inc. the controlling shareholder of blackstone holdings i/ii gp inc. is the blackstone group l.p. the sole general partner of the blackstone group l.p. is blackstone group management l.l.c. blackstone group management l.l.c. is wholly-owned by blackstone's senior managing directors and controlled by its founder, stephen a. schwarzman. |
f3 | information with respect to each of the reporting persons is given solely by such reporting person, and no reporting person has responsibility for the accuracy or completeness of information supplied by another reporting person. |
f4 | each of the reporting persons (other than clarus ii) disclaims beneficial ownership of the securities held by clarus ii, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to rule 16a-1(a)(4) under the securities exchange act of 1934, each of the reporting persons (other than clarus ii) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of section 16 or for any other purpose. |